Read by QxMD icon Read

Docetaxel carboplatin breast cancer triple negative

Sakshi Jasra, Jesus Anampa
Anthracycline-based regimens have been an important treatment component for patients with breast cancer. As demonstrated in the last Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis, anthracycline-based regimens decrease breast cancer mortality by 20-30%. Anthracycline toxicities include the rare-but potential morbid-cardiotoxicity or leukemogenic effect, and the almost universal-but very distressing-alopecia. Due to potential toxicities, and large number of patients being exposed, several worldwide trials have re-examined the role of anthracycline-based regimens in the management of breast cancer...
May 11, 2018: Current Treatment Options in Oncology
Andrew Tutt, Holly Tovey, Maggie Chon U Cheang, Sarah Kernaghan, Lucy Kilburn, Patrycja Gazinska, Julie Owen, Jacinta Abraham, Sophie Barrett, Peter Barrett-Lee, Robert Brown, Stephen Chan, Mitchell Dowsett, James M Flanagan, Lisa Fox, Anita Grigoriadis, Alexander Gutin, Catherine Harper-Wynne, Matthew Q Hatton, Katherine A Hoadley, Jyoti Parikh, Peter Parker, Charles M Perou, Rebecca Roylance, Vandna Shah, Adam Shaw, Ian E Smith, Kirsten M Timms, Andrew M Wardley, Gregory Wilson, Cheryl Gillett, Jerry S Lanchbury, Alan Ashworth, Nazneen Rahman, Mark Harries, Paul Ellis, Sarah E Pinder, Judith M Bliss
Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs DNA lesions caused by platinum agents and PARP inhibitors. Triple-negative breast cancers (TNBCs) harbor subpopulations with BRCA1/2 mutations, hypothesized to be especially platinum-sensitive. Cancers in putative 'BRCAness' subgroups-tumors with BRCA1 methylation; low levels of BRCA1 mRNA (BRCA1 mRNA-low); or mutational signatures for HR deficiency and those with basal phenotypes-may also be sensitive to platinum...
April 30, 2018: Nature Medicine
Isabel Echavarria, Sara López-Tarruella, Antoni Picornell, Jose Ángel García-Saenz, Yolanda Jerez, Katherine Hoadley, Henry L Gómez, Fernando Moreno, María Del Monte-Millan, Iván Márquez-Rodas, Enrique Alvarez, Rocío Ramos-Medina, Javier Gayarre, Tatiana Massarrah, Inmaculada Ocaña, María Cebollero, Hugo Fuentes, Agusti Barnadas, Ana Isabel Ballesteros, Uriel Bohn, Charles M Perou, Miguel Martin
Purpose: Triple-negative breast cancer (TNBC) requires the iden- tification of reliable predictors of response to neoadjuvant chemotherapy (NACT). For this purpose, we aimed to evaluate the performance of the TNBCtype-4 classifier in a cohort of patients with TNBC treated with neoadjuvant carboplatin and docetaxel (TCb). Methods: Patients with TNBC were accrued in a nonrandomized trial of neoadjuvant carboplatin AUC 6 and docetaxel 75 mg/m2 for six cycles. Response was evaluated in terms of pathologic complete response (pCR, ypT0/is ypN0) and residual cancer burden by Symmans and colleagues...
April 15, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Mai Yamada, Makoto Kubo, Masaya Kai, Hidetaka Yamamoto, Masafumi Nakamura
We report a case of TNBC treated effectively with a platinum-based regimen after developing resistance to anthracycline and taxane-based neoadjuvant chemotherapy(NAC). A 59-year-old woman with a right breast mass and high fever visited our clinic and was diagnosed as having inflammatory triple negative breast cancer(iTNBC). She was treated with NAC of docetaxel, doxorubicin, and cyclophosphamide(TAC)using pegfilgrastim. After 5 courses of TAC, the therapy failed and the disease progressed. Thus, a combination regimen of gemcitabine and carboplatin(GC)was administered...
August 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Nadia Harbeck, Oleg Gluz
Today, neoadjuvant therapy can be considered a therapy standard in triple negative (TNBC) and in HER2-positive (HER2+) (particularly in HER2+ HR-) early breast cancer (EBC). Patients with a pathological complete response (pCR) will have a very favorable outcome. In TNBC, chemotherapy with anthracyclines and taxanes is standard. Data regarding addition of bevacizumab are rather heterogeneous. Addition of carboplatin improves pCR rates independent of BRCA status; whether this will translate into a survival benefit is still unclear...
August 2017: Breast: Official Journal of the European Society of Mastology
Claudio Vernieri, Monica Milano, Alessia Mennitto, Claudia Maggi, Benvenuto Ferrari, Lucia Rinaldi, Roberta Mennitto, Claudia Stefanetti, Barbara Re, Gabriella Mariani, Giulia Bianchi, Giuseppe Capri, Filippo de Braud
BACKGROUND: Taxanes are a mainstay in the treatment of metastatic breast cancer (mBC). Combination chemotherapy, including platinum-taxens doublets, can improve tumor responses and progression-free survival (PFS), but is associated with more toxicities and an uncertain benefit in terms of overall survival (OS). METHODS: We performed a retrospective study on 274 consecutive patients with mBC treated at the Division of Medical Oncology of Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, during the decade 2007-2016 with the combination of carboplatin AUC 2 plus paclitaxel 80 mg/m(2), both given on days 1 and 8 in every 21-day cycle...
June 14, 2017: Breast Cancer Research and Treatment
Safa Najafi, Mehrdad Payandeh, Masoud Sadeghi, Vahideh Shafaei, Fateme Shojaiyan, Fereshte Abbasvandi
AIM OF THE STUDY: The aim of this trial was to compare overall survival (OS), disease-free survival (DFS), and toxicity of two adjuvant regimens in triple negative patients with Iranian ethnicity. MATERIAL AND METHODS: In a phase II trial, patients with previously untreated triple negative breaststroke cancer were randomly assigned by using docetaxel 70 mg/m(2) and carboplatin AUC = 7 every three weeks with granulocyte colony-stimulating factor for sin courses (arm A) or doxorubicin hydrochloride 60 mg/m(2) and cyclophosphamide 600 mg/m(2) every three weeks with G-CSF for four courses followed by docetaxel 70 mg/m(2) and carboplatin AUC = 7 every three weeks with G-CSF for four courses (arm B)...
2017: Contemporary Oncology Współczesna Onkologia
István Sipőcz, Tamás Pintér, Zoltán Skaliczky, Tamás Kullmann
The authors present the history of two patients. The first patient, a 69-year-old woman was diagnosed with locally invasive triple negative breast cancer with pulmonary and cerebral metastases. Complete radiological remission of the clinically asymptomatic cerebral metastases was detected under systemic chemotherapy with carboplatin-docetaxel (75 mg/m(2)). Later, the patient received whole brain radiotherapy and a second line of chemotherapy. The overall survival was 20 months from the diagnosis of cerebral metastases with conservation of partial autonomy...
November 2016: Orvosi Hetilap
Priyanka Sharma, Sara López-Tarruella, Jose Angel García-Saenz, Claire Ward, Carol S Connor, Henry L Gómez, Aleix Prat, Fernando Moreno, Yolanda Jerez-Gilarranz, Augusti Barnadas, Antoni C Picornell, Maria Del Monte-Millán, Milagros Gonzalez-Rivera, Tatiana Massarrah, Beatriz Pelaez-Lorenzo, María Isabel Palomero, Ricardo González Del Val, Javier Cortes, Hugo Fuentes Rivera, Denisse Bretel Morales, Iván Márquez-Rodas, Charles M Perou, Jamie L Wagner, Joshua M V Mammen, Marilee K McGinness, Jennifer R Klemp, Amanda L Amin, Carol J Fabian, Jaimie Heldstab, Andrew K Godwin, Roy A Jensen, Bruce F Kimler, Qamar J Khan, Miguel Martin
PURPOSE: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness of anthracycline-free platinum combinations in TNBC is not well known. Here, we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC. EXPERIMENTAL DESIGN: The study population includes 190 patients with stage I-III TNBC treated uniformly on two independent prospective cohorts...
February 1, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Neelima Denduluri, Mark R Somerfield, Andrea Eisen, Jamie N Holloway, Arti Hurria, Tari A King, Gary H Lyman, Ann H Partridge, Melinda L Telli, Maureen E Trudeau, Antonio C Wolff
PURPOSE: A Cancer Care Ontario (CCO) guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer including adjuvant targeted therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancers was identified for adaptation. METHODS: The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for adapting clinical practice guidelines developed by other organizations. The CCO guideline was reviewed for developmental rigor and content applicability...
July 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Milagros González-Rivera, Miriam Lobo, Sara López-Tarruella, Yolanda Jerez, María Del Monte-Millán, Tatiana Massarrah, Rocío Ramos-Medina, Inmaculada Ocaña, Antoni Picornell, Sonia Santillán Garzón, Lucía Pérez-Carbornero, José A García-Saenz, Henry Gómez, Fernando Moreno, Iván Márquez-Rodas, Hugo Fuentes, Miguel Martin
We describe the status and frequency of germline DNA genetic findings in an unselected prospective cohort of triple negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Study population includes 124 consecutive patients with stage II-III TNBC from a trial exploring the antitumor activity of neoadjuvant carboplatin/docetaxel chemotherapy enrolled between 2012 and March 2015, to determine the frequency of germline DNA genetic mutations. 17.1 % of the patients with germline DNA tested had deleterious mutations in any of the analyzed genes (12...
April 2016: Breast Cancer Research and Treatment
Aleix Prat, Estela Pineda, Barbara Adamo, Patricia Galván, Aranzazu Fernández, Lydia Gaba, Marc Díez, Margarita Viladot, Ana Arance, Montserrat Muñoz
Gene-expression profiling has had a considerable impact on our understanding of breast cancer biology. During the last 15 years, 5 intrinsic molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched, Basal-like and Claudin-low) have been identified and intensively studied. In this review, we will focus on the current and future clinical implications of the intrinsic molecular subtypes beyond the current pathological-based classification endorsed by the 2013 St. Gallen Consensus Recommendations...
November 2015: Breast: Official Journal of the European Society of Mastology
Peter Kern, Anne Kalisch, Gunter von Minckwitz, Carolin Pütter, Hans-Christian Kolberg, Dirk Pott, Christian Kurbacher, Mahdi Rezai, Rainer Kimmig
INTRODUCTION: Triple-negative breast cancer (TNBC) has the highest mortality rates of all subtypes. Anthracycline and taxane regimens yield unsatisfactorily low rates of pathologic complete response (pCR) and are often not feasible in cardiac comorbidity. This study seeks to increase pCR and survival by introducing platin agents. PATIENTS AND METHODS: In this multicentric, open-label study with six cycles of docetaxel (75 mg/m(2)) and carboplatin AUC 6 q3w, patients were unwilling or unsuitable for anthracycline-based regimens...
June 2016: Journal of Chemotherapy
Melinda Telli
Although not yet practice changing in early-stage triple-negative breast cancer, growing evidence suggests that neoadjuvant platinum-based therapy is active and that some patients may benefit from such an approach. Recent randomized phase III data suggests that carboplatin has comparable efficacy to docetaxel as first-line therapy in unselected advanced triple-negative breast cancer. In both settings, the efficacy of such treatment appears to be influenced by BRCA1/2 mutation status, with carriers of these mutations experiencing higher response rates...
May 2015: Journal of the National Comprehensive Cancer Network: JNCCN
Ines Vaz-Luis, Melissa E Hughes, Angel M Cronin, Hope S Rugo, Stephen B Edge, Beverly Moy, Richard L Theriault, Michael J Hassett, Eric P Winer, Nancy U Lin
BACKGROUND: Among patients with stage I breast cancer, there is significant uncertainty concerning the optimal threshold at which to consider chemotherapy, and when considered, there is controversy regarding whether to consider non-intensive versus intensive regimens. The authors examined the types and costs of adjuvant chemotherapy received among patients with stage I breast cancer. METHODS: The current study was a prospective cohort study including patients with stage I breast cancer who were treated at a National Comprehensive Cancer Network center from 2000 through 2009...
June 15, 2015: Cancer
William M Sikov
As anticipated by their structure and mechanism of action, platinum analogs exhibit clinically significant antitumor activity in the more aggressive forms of breast cancer, both alone and in combination with other cytotoxic agents and targeted therapies. In early-stage human epidermal growth factor receptor-2 (HER2)-positive breast cancer, the administration of carboplatin together with a taxane (usually docetaxel) and trastuzumab (and pertuzumab in the neoadjuvant setting) is a standard of care regimen. In BRCA1 mutation carriers, neoadjuvant treatment with single-agent cisplatin results in a high pathologic complete response (pCR) rate...
February 2015: Current Oncology Reports
Hiroshi Tsubamoto, Takashi Sonoda, Kayo Inoue
BACKGROUND/AIM: Recurrent triple-negative breast cancer (TNBC) patients have poor prognoses and limited treatment options, especially after progression during prior chemotherapy. The present study aimed to determine the impact of itraconazole with chemotherapy in these patients. PATIENTS AND METHODS: Medical records of recurrent TNBC patients receiving itraconazole with chemotherapy between 2008 and 2012 were retrospectively reviewed. RESULTS: Thirteen patients who progressed during prior chemotherapy (12 with visceral organ metastases) were enrolled...
July 2014: Anticancer Research
Peter Kern, Anne Kalisch, Hans-Christian Kolberg, Rainer Kimmig, Friederich Otterbach, Gunter von Minckwitz, William M Sikov, Dirk Pott, Christian Kurbacher
BACKGROUND: Triple-negative breast cancer (TNBC) attracts a disproportionate share of intensive research because of its poor prognosis. Standard anthracycline- and taxane-based regimens still yield an unsatisfactorily low rate of pathologic complete response (pCR). The pCR rate is a recognized surrogate marker for good long-term survival. METHODS: A multicentric, retrospective study was conducted including all patients not willing to undergo or not suitable for an anthracycline-based regimen...
2013: Chemotherapy
Patrizia Vici, Laura Pizzuti, Teresa Gamucci, Domenico Sergi, Francesca Conti, Germano Zampa, Pietro Del Medico, Roy De Vita, Marcello Pozzi, Claudio Botti, Simona Di Filippo, Federica Tomao, Isabella Sperduti, Luigi Di Lauro
PURPOSE: Chemotherapy regimens containing anthracyclines and taxanes represent the landmark of neoadjuvant systemic therapy of breast cancer. In advanced breast cancer patients liposomal anthracyclines (LA) have shown similar efficacy and less cardiac toxicity when compared to conventional anthracyclines. We performed this retrospective analysis in order to evaluate the efficacy and tolerability of neoadjuvant regimens including LA outside of clinical trials in routine clinical practice...
2014: Journal of Cancer
Ying Sun, Huan Ding, Xiao-qing Li, Li Li
OBJECTIVE: To observe the effects of poly(ADP-ribose)polymerase (PARP) inhibitor AG014699 alone and combined with docetaxel (DTX) or carboplatin (CBP) on the proliferation of triple-negative breast cancer cell line MDA-MB-231 and to investigate whether PARP inhibitor AG014699 combined with chemotherapy could play a synergistic antitumor effect. METHODS: MDA-MB-231 cells were treated by PARP inhibitor AG014699 alone or combination with DTX or CBP. Cell proliferation was measured by cell counting kit-8 assay...
April 2014: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"